Trinity Delta view: The selection of RXC008 is another reminder of the quality of Redx Pharma’s discovery platform. It is the strength of its medicinal chemistry expertise, where it has proven its ability to solve complex targeting issues, that underpins the investment case. RXC008 highlights the aim to create either best-in-class or first-in-class small molecules addressing clear needs in oncology and fibrotic diseases. Redx Pharma has a well-balanced clinical pipeline, with a mix of in-house and partnered programmes. This should provide a stream of news flow over the next 12-18 months as development progresses. Our rNPV model, based on conservative assumptions, generates a £434m ($564.7m) valuation, equivalent to 157.5p/share.
30 Mar 2022
Trinity Delta Lighthouse: Redx Pharma
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Trinity Delta Lighthouse: Redx Pharma
Redx Pharma Plc (REDX:LON), 11.8 | Redx Pharma Plc (REDX:LON), 11.8
- Published:
30 Mar 2022 -
Author:
Franc Gregori | Lala Gregorek -
Pages:
2
Trinity Delta view: The selection of RXC008 is another reminder of the quality of Redx Pharma’s discovery platform. It is the strength of its medicinal chemistry expertise, where it has proven its ability to solve complex targeting issues, that underpins the investment case. RXC008 highlights the aim to create either best-in-class or first-in-class small molecules addressing clear needs in oncology and fibrotic diseases. Redx Pharma has a well-balanced clinical pipeline, with a mix of in-house and partnered programmes. This should provide a stream of news flow over the next 12-18 months as development progresses. Our rNPV model, based on conservative assumptions, generates a £434m ($564.7m) valuation, equivalent to 157.5p/share.